The trial involving 348 samples (200 women with ovarian cancer and 148 controls) found the test to have both high specificity (87%) and high sensitivity (90%).
In addition, the test detected all subtypes and stages of ovarian cancer in the samples with the performance of the test between early-stage and late stage ovarian cancer not statistically different.
The BARD1 Ovarian Cancer Test is an ELISA-based blood test that uses a panel of peptides on a solid surface.
When exposed to a blood sample, the test measures the binding of antibodies in the patient’s blood to these peptides.
Previous data from smaller scale studies had already established the proof of concept of the test and initial indications of high sensitivity and specificity.
With high levels of accuracy shown to all stages of ovarian cancer, the BARD1 test may offer a substantial improvement over existing ovarian cancer blood tests.
The test is expected to improve the accurate detection of cancer at all stages with few false positives.
Further studies are planned to demonstrate the use of the BARD1 Ovarian Cancer Test for distinction of benign ovarian lesions and cancer.
The company is also focused on its lead product, the BARD1 Lung Cancer Test, for early detection of lung cancer utilising novel tumour markers and a proprietary algorithm.
BARD1’s closing cash balance as at 31 December 2016 was circa $1.93 million.